The revolving door is a metaphor describing the movement of people between the public and private sectors, particularly when government officials leave their positions to work for the industries they once regulated, or when industry executives take government roles overseeing their former employers. The term captures the concern that these career swaps create conflicts of interest, blur the line between regulation and industry influence, and undermine public trust. While the political meaning is the most widely known, the phrase also appears in healthcare, where it describes patients cycling in and out of hospitals without lasting improvement.
How the Revolving Door Works in Government
The basic pattern is straightforward. A regulator at a federal agency spends years learning how rules are made, who makes them, and how decisions can be influenced. They then leave government and take a job at a company or lobbying firm in the same industry they oversaw. Their inside knowledge, personal relationships, and familiarity with the regulatory process become valuable assets for their new employer. The reverse also happens: industry executives join government agencies, bringing potential biases toward the sectors they came from.
This movement is not illegal in most cases, and it can bring genuine expertise into both government and industry. But it raises a pointed question: does a regulator go easy on a company knowing they might want a job there someday? And does a former industry executive in a government seat truly regulate their old colleagues with a free hand?
The FDA as a Case Study
The U.S. Food and Drug Administration offers one of the most studied examples. A 2016 study published in The BMJ tracked 55 FDA staff who had conducted drug reviews in the blood cancer field over nine years. Of the 26 who left the agency, 15 went on to work or consult for the pharmaceutical industry. A separate investigation by the journal Science found that 11 of 16 FDA medical examiners who worked on drug approvals and then left the agency took jobs at the very companies they had recently regulated.
A more recent study linking 724 FDA reviewers’ career paths to over 1,100 drug applications between 2009 and 2019 found that the effects of the revolving door depend on seniority. Senior reviewers who later moved to industry approved lower-quality drugs, measured by the number of safety problems reported after a drug reached the market. These senior “revolvers” were also more likely to grant direct approvals, suggesting they were more lenient during the review process. Junior reviewers heading for industry, by contrast, actually spent about 15 extra days reviewing applications compared to colleagues who stayed at the agency, seemingly working harder to demonstrate their skills to future employers.
Once junior reviewers joined private companies, those firms saw improved drug quality and fewer post-market safety reports. Senior revolvers, meanwhile, helped their new employers navigate the approval process more successfully, leveraging their deep familiarity with how the FDA operates. The picture is not one of universal corruption, but of a system where personal career incentives can quietly shape decisions that affect public health.
Beyond the FDA
The revolving door operates across many agencies. At the Environmental Protection Agency, leadership positions have been filled by lobbyists and attorneys from the petroleum and chemical industries. The Lancet Oncology reported that several individuals placed in EPA oversight roles had spent years working to weaken regulation of cancer-causing products. Similar patterns show up in defense contracting, financial regulation, and telecommunications.
Cooling-Off Periods and Ethics Rules
The main policy tool for managing the revolving door is the cooling-off period: a mandatory waiting time before a former official can lobby or contact their old agency on behalf of a private client. In the United States, federal law imposes a one-year cooling-off period for former senior government employees. Cabinet-level officials face an additional two-year restriction that bars them from contacting not just their former department but any presidential appointee across the entire executive branch.
Other countries take a range of approaches. The UK requires a two-year cooling-off period for government ministers before they can take roles involving lobbying, a rule in place since 2010. Slovenia also mandates two years for lobbying roles. Ireland requires one year, but only when the new position specifically involves lobbying. Across the countries that have been assessed by governance watchdogs, cooling-off periods generally range from one to three years.
Critics argue these windows are too short. A one-year gap does little to erase the relationships and insider knowledge a former regulator carries. Supporters counter that overly long bans discourage talented people from entering public service in the first place, since they would face severe career restrictions afterward.
The Revolving Door in Healthcare
In medicine, the revolving door refers to patients who cycle through repeated hospitalizations without achieving stable recovery. The term is most commonly used in psychiatry, where a small group of patients accounts for a disproportionate share of hospital resources. Research published in The International Journal of Social Psychiatry found that revolving-door patients represent less than 10% of the total patient population but consume 20% to 30% of mental health service resources due to frequent readmissions.
Several factors predict who falls into this pattern. Younger patients, those who are single, unemployed, or have lower levels of education are more likely to experience repeated hospitalizations. Psychotic disorders (particularly schizophrenia), substance use, suicidal behavior, and difficulty sticking with treatment plans all increase the risk. Repeated hospitalization often reflects a gap between what a patient needs and what their home environment and support system can provide, rather than a failure of the hospital treatment itself.
Reducing Hospital Readmissions
Breaking the cycle requires bridging the gap between hospital and home. Care transition programs pair patients with a discharge nurse or transition coach who meets them before they leave the hospital, visits their home within two to three days, and follows up with phone calls over the next month. One well-studied version of this approach cut 30-day readmission rates from nearly 12% to about 8% and saved roughly $500 per patient.
A randomized trial at a large academic hospital tested a team-based approach: a discharge-planning nurse, a pharmacist making follow-up calls, pre-scheduled appointments, medication checks, and a plain-language instruction booklet. The rate of post-discharge hospital use dropped from 44% in the control group to 31% in the group that received these services. Patients in the intervention group were also more likely to follow up with their primary care provider, which is one of the strongest protections against readmission.
Medication reconciliation, the process of carefully reviewing every medication a patient is taking before discharge, is another critical step. Many readmissions trace back to confusion about dosages, drug interactions, or medications that were changed during the hospital stay but never clearly explained.